|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, prostate-specific membrane antigen-radioligand therapy (PSMA-RLT) is considered a last-line treatment option in advanced castration-resistant prostate cancer.
|
31579967 |
2020 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asymptomatic Metastasis to Thyroid Cartilage Detected by 18F-Choline and 64Cu-PSMA PET/CT as a Single Site of Disease Relapse in a Patient With Castration-Resistant Prostate Carcinoma.
|
31652161 |
2020 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively assessed the following PSMA-PET parameters in 43 patients before and after systemic therapies for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, and SUVpeak. prostate-specific antigen (PSA) levels and PSMA-PET/CT(magnetic resonance imaging [MRI]) imaging were both performed within 8 weeks before and 6 weeks after systemic therapy.
|
31614001 |
2020 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
|
31511295 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
|
30552200 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to bone scan, PSMA-PET is more sensitive and specific to detect metastases but the therapeutic consequences of PSMA-PET results in the setting of CRPC remain unclear.
|
30030659 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This report shows increased PSMA expression in lymph node metastases 3 months after initiation of enzalutamide for castration-resistant prostate cancer, whereas lymph node volume and serum prostate-specific antigen decreases over time.
|
31058686 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective, exploratory study, we report on the efficacy of PSMA-PET-guided local ablative radiotherapy (aRT) in 15 oligometastatic castration-resistant prostate cancer (CRPC) patients, selected from our prospective institutional database and treated between 2013 and 2016.
|
30578119 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiolabeled, low-molecular-weight prostate-specific membrane antigen (PSMA) inhibitors based on the Glu-ureido pharmacophore show promise for the detection and treatment of castration-resistant prostate cancer; however, high renal retention of activity, related in part to overexpression of PSMA in kidneys can be problematic.
|
29803076 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen PET/computed tomography and bone scintigraphy were performed for initial staging in 25 (54%), for evaluation of biochemical recurrence in 11 (24%) and metastatic castration-resistant prostate carcinoma in 10 (22%) patients.
|
31688499 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the therapeutic response, progression free survival (PFS), overall survival (OS) and clinical toxicity of <sup>177</sup>Lu-PSMA-617 PSMA targeted radioligand therapy (PRLT) in the setting of heavily pre-treated metastatic castrate-resistant prostate cancer (mCPRC) patients and also examine the association of prognostic variables with therapeutic outcome in such patient cohort.
|
31600089 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the establishment and characterization of an AR+, PSMA+, ERG+, PTEN<sup>-/-</sup>, CHD1<sup>+/-</sup> patient-derived xenograft (PDX) model termed 'C5', which has been developed from a 60 years old patient suffering from castration-resistant prostate cancer (CRPC).
|
30510249 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a novel template for PSMA targeted CRPC therapy, either using cytostatics or radionuclides.
|
29491082 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
|
30059428 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
|
29989440 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recommend that <sup>68</sup>Ga-PSMA PET/CT should be performed in primary staging together with pelvic mpMR in high-risk patients and in all patients for secondary staging, and that PSMA-directed therapy is a potent strategy in CRPC patients when other treatment options have failed.
|
29282518 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the value of <sup>68</sup>Ga-HBED-CC PSMA (<sup>68</sup>Ga-PSMA) PET/CT for response assessment in metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) during docetaxel chemotherapy.
|
29185010 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer.
|
29465494 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen radioligand therapy with Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival.
|
30036254 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The <sup>68</sup>Ga/<sup>177</sup>Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV<sub>max</sub> values and absorbed dose estimates.
|
28083690 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study thus aimed to assess the pharmacokinetics and dosimetry of Lu-DKFZ-PSMA-617 in CRPC patients.
|
27782913 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
|
27587707 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results establish that relative changes in PSMA expression levels can be quantitatively measured using a human-ready imaging reagent and could serve as a biomarker of AR signaling to noninvasively evaluate AR activity in patients with CRPC.
|
21606347 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of the AR regulated proteins PSA and PSMA were marginally affected by the decrease in C-terminal staining in CRPC samples.
|
22114732 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate specific membrane antigen (PSMA) expression correlates with prostate cancer grade and is increased in hormone-refractory prostate cancer.
|
18247401 |
2008 |